Neuroendocrine tumors, kidney, liver, pancreatic, bladder, and breast cancer
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, kidney cancer, pancreatic, bladder, and breast cancers.
Spasticity in adults and children, cervical dystonia, hemifacial spasm, cerebral palsy
Ipsen is one of the global leaders in the discovery, development, manufacture and commercialization of neurotoxins. Neuroscience is core to Ipsen’s specialty care business and is integral to the company’s overall strategy and long‐term growth.
Pituitary pathologies and growth disorders
Ipsen continues to develop innovative medicines in rare diseases to address conditions with high unmet needs, with specific investment in pituitary pathologies and growth disorders.
Gastrointestinal disorders, neurodegenerative pathologies and rheumatology
Ipsen’s long-standing expertise spans the value chain, from active principle to finished product to the patient, with special expertise in gastrointestinal (GI) disorders, neurodegenerative pathologies and rheumatology, as well as a constantly expanding portfolio. We are also establishing a growing sustainable and autonomous Consumer Healthcare business.
Research & Development
Ipsen’s commitment to research & development is our bold promise to patients to launch at least one new drug or meaningful new indication every year. We will secure our future by building a pipeline of innovative medicines.